Jan Geliebter

Title: Innovations by Jan Geliebter: Pioneering Immunological Advancements

Introduction

Jan Geliebter is an accomplished inventor based in Brooklyn, NY, recognized for his significant contributions to the field of immunology. With a robust portfolio of five patents, Geliebter has made substantial strides in developing innovative solutions for immune response elicitation and cancer treatment.

Latest Patents

Among Jan Geliebter's latest patents is the invention of synthetic toll-like receptor-4 (TLR-4) agonist peptides. This groundbreaking invention provides novel immunological adjuvants and methodologies for identifying such adjuvants. The patented technology includes methods and compositions aimed at eliciting an immune response to diverse immunogens, including proteins, peptides, lipids, and carbohydrates. Notably, these immunogens can be derived from viruses, cancers, or diseased cells, enabling the elicited immune response to be cellular, humoral, or a combination of both.

Another significant patent focuses on immunotherapy for prostate cancer using recombinant Bacille Calmette-Guerin (BCG) expressing prostate-specific antigens. This invention relates to effective treatment strategies for prostate cancer and metastatic disease, providing methods and compositions that harness potent immune responses against prostate-specific antigens.

Career Highlights

Jan Geliebter has an impressive career that highlights his dedication to scientific innovation. He has held prestigious positions at various institutions, including the Albert Einstein College of Medicine and Immunotech. His work primarily revolves around the intersection of immunology and cancer research, where he has successfully translated scientific discoveries into practical therapeutic applications.

Collaborations

Throughout his career, Jan Geliebter has collaborated with notable professionals, including Arnold Melman. Together, they have worked on advancing methods and strategies to improve immune response and tackle complex medical challenges, particularly in cancer treatment.

Conclusion

Jan Geliebter's inventive contributions significantly enhance the field of immunology, particularly pertaining to cancer therapies. His patents represent cutting-edge advancements that could lead to more effective treatments and improve patient outcomes. As he continues to innovate, Geliebter's work is poised to impact significantly the future of immunotherapy and cancer management.